Kilitch Drugs (India) Limited (NSE:KILITCH)

Market Cap	5.80B
Revenue (ttm)	2.08B
Net Income (ttm)	283.86M
Shares Out	n/a
EPS (ttm)	17.66
PE Ratio	20.42
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,960
Average Volume	15,010
Open	371.95
Previous Close	366.15
Day's Range	358.70 - 371.95
52-Week Range	299.95 - 500.00
Beta	-0.19
RSI	36.00
Earnings Date	Nov 14, 2025

About Kilitch Drugs (India)

Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India, Asia, Africa, Latin America, and Commonwealth of Independent States. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-inflammatory, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anest...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 168
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: KILITCH

Financial Performance

In 2024, Kilitch Drugs (India)'s revenue was 1.98 billion, an increase of 28.47% compared to the previous year's 1.54 billion. Earnings were 267.01 million, an increase of 82.86%.